Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008761 | 0.75 | AKR1C4 (0.43) | ALDH1A1MEN1KMT2AHPGDTSHR | |
| SCHEMBL30810022 | 0.74 | P2RX7 (0.54) | P2RX7NPC1HSD11B1ALDH1A1MEN1 | |
| SCHEMBL30691934 | 0.74 | P2RX7 (0.54) | P2RX7NPC1HSD11B1ALDH1A1MEN1 | |
| SCHEMBL30009357 | 0.74 | TSHR (0.38) | ALDH1A1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL31454276 | 0.74 | P2RX7 (0.54) | P2RX7NPC1HSD11B1ALDH1A1MEN1 | |
| SCHEMBL30009295 | 0.74 | JAK1 (0.43) | NPC1ALDH1A1HPGDTSHRJAK1 | |
| SCHEMBL31646988 | 0.72 | HSD11B1 (0.56) | P2RX7NPC1HSD11B1ALDH1A1MEN1 | |
| SCHEMBL31454267 | 0.72 | HSD11B1 (0.56) | P2RX7NPC1HSD11B1ALDH1A1MEN1 | |
| SCHEMBL30009886 | 0.70 | JAK1 (0.39) | NPC1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL30009910 | 0.70 | JAK1 (0.40) | NPC1HSD11B1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | P2RX7 3396/4885NPC1 1715/4885HSD11B1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.